Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYTODEX: PK and Cytokine Response of Dextenza in Cataract Surgery
NCT04667507Phase 4Completed
- Start
- Jan 2021
- Primary completion
- Oct 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ozurdex in post-operative ocular inflammation and post-operative ocular pain. Started Jan 2021; status: completed.
02
Drugs
ozurdex
03
Conditions
post-operative ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NCT04667507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667507.